*September 2017 – for immediate release Further information: Chris Pockett, +44 1453 524133*

***neuroinspire*™ stereotactic neurosurgery planning standalone software cleared for sale in the USA**

Renishaw is pleased to announce that the Food and Drug Administration (FDA) has cleared the latest version of *neuroinspire* stereotactic neurosurgery planning standalone software for sale in the USA.

*neuroinspire* software fuses MRI and CT datasets into a 3D volume, enabling neurosurgeons to identify and outline regions of interest, and determine the best available approach to the target. Thorough planning in the pre-operative stage can minimise the chance of hitting key anatomy during the procedure, and improve patient outcomes.

The *neuroinspire* software can be used to plan a range of stereotactic procedures and assist neurosurgeons to target anatomy concealed deep within the brain tissue. Neurosurgeons using *neuroinspire* can create plans based on procedure type, with planning tools tailored to the task in hand. Users can choose to work on a Deep Brain Stimulation (DBS) to reduce the symptoms of Parkinson’s disease, a Stereoelectroencephalography (SEEG) to identify the area of the brain responsible for epileptic seizures or a biopsy to assist with the diagnosis of a brain tumour.

On the FDA’s decision, Head of Regulatory Affairs and Quality Assurance Roberto Liddi commented, “The success of the clearance application was the result of a great team effort across all areas of the Renishaw Neurological Products Division. We are delighted that *neuroinspire* standalone software is now available on the American market, and look forward to working with neurosurgeons in the USA to streamline complex neurosurgical procedures.”

The latest version of *neuroinspire* software supports more data formats than previous versions of the software, and features semi-automatic profiling which allows surgeons to quickly and intuitively delineate anatomical features.

Additional modules for *neuroinspire* software are available, including region of interest based automatic registration, PACS connectivity for retrieving patient data from the hospital network and the Cerefy Electronic Clinical Brain Atlas for cross-referencing target placement.

**About Renishaw**

UK-based Renishaw is a world leading engineering technologies company, supplying products used for applications as diverse as jet engine and wind turbine manufacture, through to facial reconstruction and neuro surgery. It has over 4,000 employees located in the 35 countries where it has wholly owned subsidiary operations.

For the year ended June 2017 Renishaw recorded sales of £536.8 million of which 95% was due to exports. The company’s largest markets are China, the USA, Japan and Germany.

Throughout its history Renishaw has made a significant commitment to research and development, with historically between 14 and 18% of annual sales invested in R&D and engineering. The majority of this R&D and manufacturing of the company’s products is carried out in the UK.

The Company’s success has been recognised with numerous international awards, including eighteen Queen’s Awards recognising achievements in technology, export and innovation.

For further information on Renishaw’s range of products for stereotactic neurosurgery, visit [www.renishaw.com/neuro](http://www.renishaw.com/neuro)

**-ENDS-**